IPSC - Century Therapeutics, Inc.
About Century Therapeutics, Inc. (https://www.centurytx.com)
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Brent Pfeiffenberger | President, Chief Executive Officer & Chairman | 1978 | $971,732 USD |
| Gregory Russotti | Chief Technology & Manufacturing Officer | 1967 | $789,960 USD |
| Chad A. Cowan | Chief Scientific Officer | 1972 | $760,539 USD |
| Douglas Carr | Senior VP of Finance & Operations, Principal Financial Officer and Secretary | – | – |
| Elizabeth Devlin | Vice President & Head of Development | – | – |
| Krista Kauppinen | VP, General Counsel & Head of Intellectual Property | – | – |
| Megan Bilson | Chief People Officer | – | – |
| Michael Naso | Senior Vice President of Cell Engineering | – | – |